Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
2seventy bio, Inc. is a cell therapy company focused on the commercialization of Abecma, the first FDA-approved CAR T cell therapy for multiple myeloma. With a significant market opportunity, the company targets patients with relapsed or refractory disease. Recent strategic initiatives include partnerships with Bristol-Myers Squibb for commercialization and the sale of non-core assets to enhance focus on Abecma's development and market presence.
This description was generated via AI from an annual report. Updated about 1 year ago.